As of 2024-12-14, the Relative Valuation of VistaGen Therapeutics Inc (VTGN) is (32.22) USD. This relative valuation is based on P/E multiples. With the latest stock price at 2.48 USD, the upside of VistaGen Therapeutics Inc based on Relative Valuation is -1399.4%.
The range of the Relative Valuation is (29.79) - (27.63) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.0x - 31.3x | 26.2x |
| Forward P/E multiples | 19.0x - 19.4x | 19.2x |
| Fair Price | (29.79) - (27.63) | (32.22) |
| Upside | -1301.1% - -1214.0% | -1399.4% |
| Date | P/E |
| 2024-11-29 | -2.00 |
| 2024-11-27 | -1.89 |
| 2024-11-26 | -1.83 |
| 2024-11-25 | -1.92 |
| 2024-11-22 | -1.82 |
| 2024-11-21 | -1.78 |
| 2024-11-20 | -1.84 |
| 2024-11-19 | -1.88 |
| 2024-11-18 | -1.86 |
| 2024-11-15 | -1.85 |
| 2024-11-14 | -1.92 |
| 2024-11-13 | -1.98 |
| 2024-11-12 | -2.06 |
| 2024-11-11 | -2.13 |
| 2024-11-08 | -2.21 |
| 2024-11-07 | -2.20 |
| 2024-11-06 | -2.18 |
| 2024-11-05 | -2.22 |
| 2024-11-04 | -2.27 |
| 2024-11-01 | -2.19 |
| 2024-10-31 | -2.17 |
| 2024-10-30 | -2.17 |
| 2024-10-29 | -2.15 |
| 2024-10-28 | -2.13 |
| 2024-10-25 | -2.12 |
| 2024-10-24 | -2.13 |
| 2024-10-23 | -2.13 |
| 2024-10-22 | -2.18 |
| 2024-10-21 | -2.11 |
| 2024-10-18 | -2.16 |
| 2024-10-17 | -2.15 |
| 2024-10-16 | -2.13 |
| 2024-10-15 | -2.05 |
| 2024-10-14 | -2.13 |
| 2024-10-11 | -2.13 |
| 2024-10-10 | -2.13 |
| 2024-10-09 | -2.05 |
| 2024-10-08 | -2.07 |
| 2024-10-07 | -2.02 |
| 2024-10-04 | -2.12 |
| 2024-10-03 | -2.08 |
| 2024-10-02 | -2.11 |
| 2024-10-01 | -2.15 |
| 2024-09-30 | -2.12 |
| 2024-09-27 | -2.16 |
| 2024-09-26 | -2.11 |
| 2024-09-25 | -2.15 |
| 2024-09-24 | -2.12 |
| 2024-09-23 | -2.13 |
| 2024-09-20 | -2.22 |